Business & Finance
NeuroVive Pharmaceutical widens loss in Q3 2018
23 November 2018 -

Mitochondrial medicine company NeuroVive Pharmaceutical AB (STO:NVP) reported on Thursday loss before tax of SEK14,982,000, or SEK0.20 per diluted share, for the third quarter of 2018, from July 2018 to September 2018.

This was a decline over loss before tax of SEK13,179,000, or SEK0.26 per diluted share, in Q3 2017.

Net revenues from the quarter were nil, same as in Q3 2017.

During January 2018 to September 2018, NeuroVive received positive FDA feedback on its NeuroSTAT TBI development plan, NeuroVive and Yungjin reported positive KL1333 phase I clinical study result and KL1333 received FDA Orphan Drug Designation for treatment of mitochondrial diseases.